Category

Industry News

Home / Industry News

Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with a History of Inadequate Response

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-07, Axsome’s novel, oral, multi-mechanistic investigational medicine for the acute treatment of migraine, met the two regulatory co-primary endpoints and significantly improved migraine pain and most bothersome symptoms as compared to placebo in the MOMENTUM Phase 3 trial.

1 2 3 4 5 6
Pain Medicine Journal
Access to this page is restricted to members only! Not a mamber? Join Now!

Ask Us Anything. Anytime.

📝 Fill in your details and we’ll get back to you in no time.
AAPM

American Academy of Pain Medicine